Myrbetriq is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Cardinal Health. The primary component is Mirabegron.
Product ID | 55154-8713_1b9ded22-d5c2-4380-8de6-1ff4a48da75f |
NDC | 55154-8713 |
Product Type | Human Prescription Drug |
Proprietary Name | Myrbetriq |
Generic Name | Mirabegron |
Dosage Form | Tablet, Film Coated, Extended Release |
Route of Administration | ORAL |
Marketing Start Date | 2012-06-28 |
Marketing Category | NDA / NDA |
Application Number | NDA202611 |
Labeler Name | Cardinal Health |
Substance Name | MIRABEGRON |
Active Ingredient Strength | 50 mg/1 |
Pharm Classes | beta3-Adrenergic Agonist [EPC],Adrenergic beta3-Agonists [MoA],Cytochrome P450 2D6 Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2012-06-28 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA202611 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2012-06-28 |
Ingredient | Strength |
---|---|
MIRABEGRON | 50 mg/1 |
SPL SET ID: | aaaf3bea-1b21-4edf-9300-b7159ea9ede8 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0469-2601 | Myrbetriq | mirabegron |
0469-2602 | Myrbetriq | mirabegron |
0469-5020 | Myrbetriq | mirabegron |
55154-8712 | Myrbetriq | mirabegron |
55154-8713 | Myrbetriq | mirabegron |
70518-2435 | Myrbetriq | mirabegron |
70518-3158 | Myrbetriq | mirabegron |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
MYRBETRIQ 85595770 4263728 Live/Registered |
Astellas Pharma Inc. 2012-04-12 |